A new approach to tackling solid tumours has attracted significant early investment for Signadori Bio. The Paris-based preclinical biopharmaceutical company announced it has closed a $13.1M Seed funding round, with capital coming from Taiho Oncology and Sofinnova Partners.
Signadori Bio, founded by Dr Jean-Luc Perfettini and Professor Nathalie Chaput, is developing a next-generation, off-the-shelf, in vivo engineered monocyte immunotherapy platform. Based on research from Gustave Roussy, its technology aims to overcome the challenges of the tumour microenvironment by harnessing gene-modified monocytes.













